The Company expects fourth quarter 2025 revenue of approximately $2.87 billion, an increase of 19% compared with $2.41 billion in the fourth quarter of 2024. The higher fourth quarter revenue was ...
Worldwide procedures (da Vinci and Ion combined) grew approximately 20% compared with the third quarter of 2024. Da Vinci procedures grew approximately 19% and Ion procedures grew approximately 52%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results